CS
NAUT icon

Candriam SCA’s Nautilus Biotechnolgy NAUT Stock Holding History

Candriam SCA’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-155,000
Closed -$803K – 831
2021
Q4 		$803K Hold
155,000
– – 0.01% 700
2021
Q3 		$952K Hold
155,000
– – 0.01% 710
2021
Q2 		$1.57M Buy
+155,000
New +$1.68M 0.01% 632

Other funds holding NAUT

AEPBI
AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return
AEPLI
AH Equity Partners LSV II Menlo Park, California $95.6M AUM 8.86% 1-Year Est. Return

Candriam SCA's NAUT Position: Q1 2022 in Review

Candriam SCA sold out of Nautilus Biotechnolgy (NAUT) in Q1 2022, closing a stake of 155,000 shares — an estimated $803K sold.

Candriam SCA first reported a position in NAUT in Q2 2021 and held it in 3 quarters. The position peaked at $1.57M in Q2 2021. 82 funds tracked by Wall St. Rank hold NAUT as of Q1 2022.

  • Candriam SCA reported no remaining Nautilus Biotechnolgy position as of Q1 2022 after selling out during the quarter.
  • Candriam SCA sold 155,000 Nautilus Biotechnolgy shares in Q1 2022, an estimated $803K.
  • Candriam SCA first reported a position in Nautilus Biotechnolgy in Q2 2021 and held it in 3 quarters.
  • Candriam SCA's Nautilus Biotechnolgy position peaked at $1.57M in Q2 2021.
  • 82 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2022.

Based on Candriam SCA's 13F filing for Q1 2022, filed 13 May 2022.